Press Release

Astellas Announces Personnel Changes and

Organizational Changes

Tokyo, February 5, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the personnel changes and organizational changes as below.

1. Appointments of Senior Corporate Executive effective April 1, 2018

Name

New Title

Current Title

Chihiro Yokota

CEO's Office

Head of Japan-Asia Development,

Development

Wataru Uchida

CEO's Office

Head of Drug Discovery Research

Makoto Takeuchi

CEO's Office

Senior Vice President, External Relations

CEO: Chief Executive Officer

2. Appointments of Corporate Executive effective April 1, 2018

Name

New Title

Current Title

Kazunori Okimura

CEO's Office

Corporate Vice President, Legal

Katsumi Ozawa

CEO's Office

General Manager, Tokyo Branch, Japan Sales &

Marketing

Chikashi Takeda

CFO and Head of Finance

CFO

Fumiaki Sakurai

CAO & CECO and Head of Human Resources

CAO & CECO

Naoki Okamura

CSTO

Corporate Vice President,

Corporate Planning

Akihiko Iwai

Head of Drug Discovery Research

Divisional Senior Vice President,

Candidate Discovery Science Labs., Drug Discovery Research

Shigeki Tanaka

Head of Japan-Asia Development,

Development

Vice President, Japan-Asia

Clinical Development 1,

Development

Atsushi Kamide

Vice President, External Relations

Vice President, Healthcare

Policy & CSR

CFO: Chief Finance Officer

CAO: Chief Administrative Officer CECO: Chief Ethics & Compliance Officer CSTO: Chief Strategy Officer

1

3. Resignation of Senior Corporate Executive effective June 15, 2018

Name

Title (effective on April 1, 2018)

Chihiro Yokota

CEO's Office

Wataru Uchida

CEO's Office

Makoto Takeuchi

CEO's Office

4. Resignation of Corporate Executive effective June 15, 2018

Name

Title (effective on April 1, 2018)

Kazunori Okimura

CEO's Office

Katsumi Ozawa

CEO's Office

5. Appointment of Senior Corporate Executive effective June 15, 2018

Name

Title (effective on April 1, 2018)

Chikashi Takeda

CFO and Head of Finance

Nobuaki Tanaka

Head of Japan Sales & Marketing

Akihiko Iwai

Head of Drug Discovery Research

Atsushi Kamide

Senior Vice President, External Relations

6. New Corporate Executives effective June 15, 2018

Name

Title (effective on April 1, 2018)

Shiro Yamamoto

General Manager, Tokyo Branch, Japan Sales & Marketing

Masaaki Hirano

Corporate Vice President, Corporate Planning

Yoshitsugu Shitaka

President, Astellas Institute for Regenerative Medicine

7. Personnel Changes effective April 1, 2018

Name

New Title

Current Title

Kazuhiko Kawasaki

Head of Internal Auditing and Vice President, Internal Auditing

Vice President, Internal Auditing

Masaaki Hirano

Corporate Vice President,

Corporate Planning

Divisional Senior Vice President, Modality Research Labs., DDR

Yuta Watanabe

Vice President, Rx+ Business

Accelerator

Vice President, Japan-Asia Planning & Administration, Medical & Development

Osamu Chihara

Vice President, Healthcare

Policy & CSR

Senior Director, Healthcare

Policy & CSR

Stig Ogata

Vice President, Corporate

Communications

Senior Director, Business Strategy & Operations,

Marketing Strategy Astellas Pharma US, Inc.

Satoshi Nozaki

Vice President, Legal

Staff Executive Director, Legal

Minori Saitoh

Vice President, Research Planning & Administration, DDR

Vice President, Drug Repurposing and Application

Management, DDR

Taro Masunaga

Vice President, Research Portfolio Planning, DDR

Executive Director, Innovation &

Incubation Research Labs.,

DDR

Tatsuaki Morokata

Divisional Senior Vice President,

Innovation & Incubation Research Labs., DDR

Executive Director, Product &

Portfolio Strategy

Yuichi Tomura

Divisional Senior Vice President,

Candidate Discovery Science

Labs., DDR

Vice President, Research Portfolio Planning, DDR

Shigeki Kawabata

Vice President, New Medical

Solutions, DDR

Vice President, Evolving Medical Solutions, DDR

Noriyuki Masuda

Divisional Senior Vice President, Modality Research Labs., DDR

Vice President, Research Planning & Administration, DDR

Shigeru Nakaji

Vice President, Japan-Asia Planning & Administration, Medical & Development

Executive Director, Japan-Asia

Clinical Development 1,

Development

Hiroaki Ishikura

Vice President, Japan-Asia

Clinical Development 1,

Development

Senior Director, Japan-Asia

Clinical Development 1,

Development

Kei Motonaga

Vice President, Analytical

Research Laboratories, Pharmaceutical Technology

Senior Director, Quality Control

Division, Yaizu Technology

Center

Koji Nagao

Vice President, Pharmaceutical Science & Technology Labs., Pharmaceutical Technology

Pharmaceutical Technology

Masaaki Usui

Divisional Senior Vice President,

Product Marketing, Japan Sales & Marketing

Vice President, Corporate

Communications

Shiro Yamamoto

General Manager, Tokyo Branch, Japan Sales &

Marketing

Divisional Senior Vice President,

Product Marketing, Japan Sales & Marketing

Takashi Matsuki

Vice President, Business Planning, Asia & Oceania

Business

President, P.T. Astellas Pharma

Indonesia

DDR: Drug Discovery Research

[Staff Executive Director]

Name

New Title

Current Title

Masahiro Takeuchi

Staff Executive Director, DDR

Executive Director, Candidate Discovery Science Labs., DDR

Tomoyuki Yasunaga

Staff Executive Director, Planning & Administration, DDR

Executive Director, Planning &

Administration, DDR

Hideto Yamaguchi

Staff Executive Director, Pharmaceutical Technologies

Senior Director, Pharmaceutical Technologies

8. Organizational Changes effective April 1, 2018

Establishment of Rx+ Business Accelerator

To create new business models for Rx+ (innovative medical solutions by combining a variety of internal and external capabilities) and build business case capability, implement idea-seeking collaborations and create processes to manage Rx+ projects, a special team within Corporate Planning will be reorganized into the Rx+ Business Accelerator.

Changes to Drug Discovery Research

To ensure reliability and increase the efficiency of research program management, the application management function of Drug Repurposing will be transferred to Research Program Management. The drug repurposing research function of Drug Repurposing will be in transferred to EMed, and Drug Repurposing will be effectively dissolved. EMed will be transferred to New Medical Solutions, and serve as a research function, including drug repurposing research of new medical solutions.

Establishment of Pharmaceutical Science & Technology Labs

To shorten the time from discovery to Proof-of-Concept (POC), a part of functions / staff at the current four Labs (Process Chemistry Labs, Biotechnology Labs, Pharmaceutical Research & Technology Labs and Analytical Science Labs) in Pharmaceutical Technologies will be transferred / integrated into Pharmaceutical Science & Technology Labs (PSTL). The PSTL will have flexibility to respond to every modality within the five Labs. structure of Pharmaceutical Technologies.

###

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website atwww.astellas.com/en.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473

Astellas Pharma Inc. published this content on 05 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 February 2018 05:09:01 UTC.

Original documenthttps://www.astellas.com/en/corporate/news/pdf/180205_2_Eg.pdf

Public permalinkhttp://www.publicnow.com/view/D45194D30671C09A19D082C552789B4A8811DCD6